Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

Gout Flares & the NLRP3 Inflammasome

Katie Robinson  |  May 30, 2025

Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as new treatment option.

Filed under:ConditionsGout and Crystalline ArthritisResearch ReviewsResearch Rheum Tagged with:Arthritis & Rheumatologycase reportGoutGout Resource CenterImmunology InsightsNACHT-LRR-PYD-containing protein 3NLRP3

COVID-19 & Rheumatic Disease Flare

From the College  |  May 8, 2025

FDA Approves Oral Solution of Colchicine to Prevent Gout Flare

Michele B. Kaufman, PharmD, BCGP  |  April 9, 2025

The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.

Filed under:AnalgesicsConditionsDrug UpdatesGout and Crystalline Arthritis

Editor's Pick

Large International Study Says Flares Rare After COVID Vaccination

Catherine Kolonko  |  April 3, 2025

‘Patients with rheumatologic diseases are rightfully concerned about the risk of flares after getting their COVID vaccines, especially after holding immune modulators,’ says says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘A new study is reassuring that flares are rare, even after holding or discontinuing immune modulators.’ The development of a vaccine for…

Filed under:ConditionsResearch Rheum Tagged with:COVID-19Flaresresearch reviewsvaccination

Flares Rare After COVID Vaccination

Catherine Kolonko  |  March 7, 2025

The development of a vaccine for COVID-19 changed the course of the pandemic; however, it also raised questions about whether to withhold or reduce immunosuppressive therapies and other medications for patients with inflammatory, rheumatic and musculoskeletal disease (IRMD), note the authors of a new study published in Annals of the Rheumatic Diseases. An argument for…

Filed under:Clinical Criteria/GuidelinesConditionsGuidanceGuidelinesResearch ReviewsResearch Rheum Tagged with:COVID-19flarevaccination

How to Reduce Gout Flares

Keri Losavio  |  November 12, 2023

SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2023Gout Resource Center

FDA Approves Canakinumab to Treat Gout Flares

Michele B. Kaufman, PharmD, BCGP  |  November 3, 2023

Canakinumab has received FDA approval for the treatment of patients with acute gout flares.

Filed under:Biologics/DMARDsDrug UpdatesGout and Crystalline Arthritis Tagged with:canakinumabFDA approvalGout Resource CenterU.S. Food and Drug Administration (FDA)

Almost Half of Patients with RA Experience Flare after Glucocorticoid Discontinuation

Lara C. Pullen, PhD  |  October 25, 2022

In a post hoc analysis of two clinical trials, Maassen et al. demonstrated that 40% of patients with early RA or undifferentiated arthritis experienced disease flare after primary glucocorticoid discontinuation despite background treatment with conventional synthetic DMARDs.

Filed under:ConditionsRheumatoid Arthritis Tagged with:discontinuationflareglucocorticoidRA flaresRheumatoid Arthritis (RA)

Patterns of Arthritis Flare

Arthritis & Rheumatology  |  September 28, 2022

Similar patterns of inflammation occur in the joints of patients with inflammatory arthritis, but in each individual, arthritis affects only a subset of possible anatomic areas. Chang et al. set out to identify patient-specific anatomic patterns of joint flare to distinguish local from systemic drivers of chronic disease.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis & Rheumatologyflarejuvenile idiopathic arthritis (JIA)RA flaresResearchRheumatoid Arthritis (RA)

Updated Perioperative Guideline Released: Recommendations Balance Risks of Infection & Disease Flare

Ruth Jessen Hickman, MD  |  September 13, 2022

The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:guidelinePerioperative Management of Anti-Rheumatic Medications in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Knee Arthroplastytotal hip arthroplastytotal knee arthroplasty

  • 1
  • 2
  • 3
  • …
  • 68
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences